CG Oncology, Inc. Common stock

CG Oncology announced the publication of results from its pivotal Phase 3 BOND-003 Cohort C trial evaluating cretostimogene grenadenorepvec monotherapy in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ in The Lancet Oncology. The trial met its primary endpoint with a complete response rate of 75.5 percent at any time, a median duration of response of at least 27.9 months that is ongoing, and 12- and 24-month duration of response rates of 64.2 percent and 60.1 percent respectively. No Grade 3 or greater treatment-related adverse events were reported, and 96.6 percent of patients were free from progression to muscle invasive bladder cancer at both 48 and 96 weeks. The company stated that if approved, cretostimogene may represent an important bladder-sparing advancement in the treatment paradigm.

RTTNews highlights five biotech and medical device stocks that generated returns of 86% to 327% since being featured on its website. Arrowhead Pharmaceuticals surged 222% to a 52-week high of $95.49 following FDA approval of its lead drug Redemplo and positive clinical data. Compass Pathways climbed 327% to a 3.5-year high of $15.40 after reporting positive Phase 3 results for its psilocybin therapy COMP360 in treatment-resistant depression. CG Oncology rose 148% to an all-time high of $77.00 on the back of encouraging data for its bladder cancer candidate Cretostimogene. Alpha Tau Medical gained 182% to a 52-week high of $14.11 driven by regulatory progress and promising clinical results for its Alpha DaRT cancer therapy. Electromed advanced 86% to a 52-week high of $47.40 supported by strong quarterly revenue and profit growth.

Two stocks have drawn attention after directors made multimillion-dollar insider purchases. At CG Oncology, board member Brian Guan-Chyun Liu bought 371,085 shares for about $24.8 million on June 25, as the company advances its bladder cancer drug cretostimogene toward a Biologics License Application submission in the fourth quarter of 2026. JPMorgan analyst Brian Cheng rates the stock Overweight with a $96 price target, implying 35% upside, while the broader analyst consensus is a Strong Buy with an average target of $91.55. At Adobe, director David Ricks purchased 10,000 shares for nearly $1.95 million on the same day, bringing his total stake to roughly $4.5 million, even as the stock has fallen 37% year-to-date amid a CEO transition, a shift to a freemium model, and AI disruption concerns. Adobe reported record fiscal second-quarter revenue of $6.62 billion, up 13% year-over-year, and raised its full-year guidance, with Bernstein analyst Mark Moerdler maintaining an Outperform rating and a $379 price target that suggests 72% upside. The consensus rating on Adobe is a Hold, with an average price target of $260.11, indicating 18% upside from the current price of $219.72.

Cancer treatment is undergoing a major transformation as a new generation of biotechnology companies develops smarter, more targeted therapies. BioNTech, known for its COVID-19 vaccine, has expanded into oncology with mRNA cancer vaccines and personalized immunotherapies. Summit Therapeutics has seen success with ivonescimab, a novel immunotherapy for lung cancer. CG Oncology is working on an oncolytic immunotherapy platform for bladder cancer. NeOnc Technologies is developing targeted oncology therapies for significant unmet medical needs. These four companies represent different facets of a broader movement toward more personalized and innovative cancer care.

The non-muscle invasive bladder cancer market is expected to undergo significant transformation during the 2026 to 2036 forecast period as novel targeted and gene therapies advance through late-stage clinical development. The total market size across the seven major markets, comprising the United States, the EU4 countries of Germany, France, Italy, and Spain, the United Kingdom, and Japan, was approximately USD 3 billion in 2025, with the United States holding the largest share. Total prevalent cases of non-muscle invasive bladder cancer in these markets were nearly 1.56 million and are projected to increase by 2036. Key emerging therapies include CG0070 from CG Oncology, EG-70 from enGene, TAR-210 from Janssen, Dabogratinib from Tyra Biosciences, UGN-103 from UroGen Pharma, and TARA-002 from Protara Therapeutics, with cretostimogene grenadenorepvec plus or minus KEYTRUDA expected to generate the highest revenue among all therapies by 2036.